Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 26;13(11):1870.
doi: 10.3390/diagnostics13111870.

Arterial Stiffness as a Surrogate Marker of Cardiovascular Disease and Atherosclerosis in Patients with Arthritides and Connective Tissue Diseases: A Literature Review

Affiliations
Review

Arterial Stiffness as a Surrogate Marker of Cardiovascular Disease and Atherosclerosis in Patients with Arthritides and Connective Tissue Diseases: A Literature Review

Konstantinos Triantafyllias et al. Diagnostics (Basel). .

Abstract

The increased cardiovascular (CV) risk among patients with autoimmune rheumatic diseases, such as arthritides and connective tissue diseases, has been extensively documented. From a pathophysiological standpoint, systemic inflammation in the context of the disease can lead to endothelial dysfunction, accelerated atherosclerosis, and structural changes in vessel walls, which, in turn, are associated with exaggerated CV morbidity and mortality. In addition to these abnormalities, the increased prevalence of traditional CV risk factors, such as obesity, dyslipidemia, arterial hypertension, and impaired glucose metabolism, can further worsen the status of and overall prognosis for CV in rheumatic patients. However, data on appropriate CV screening methods for patients with systemic autoimmune diseases are scarce, and traditional algorithms may lead to an underestimation of the true CV risk. The reason for this is that these calculations were developed for the general population and thus do not take into account the effect of the inflammatory burden, as well as other chronic-disease-associated CV risk factors. In recent years, different research groups, including ours, have examined the value of different CV surrogate markers, including carotid sonography, carotid-femoral pulse wave velocity, and flow-mediated arterial dilation, in the assessment of CV risk in healthy and rheumatic populations. In particular, arterial stiffness has been thoroughly examined in a number of studies, showing high diagnostic and predictive value for the occurrence of CV events. To this end, the present narrative review showcases a series of studies examining aortic and peripheral arterial stiffness as surrogates of all-cause CV disease and atherosclerosis in patients with rheumatoid and psoriatic arthritis, as well as in systemic lupus erythematosus and systemic sclerosis. Moreover, we discuss the associations of arterial stiffness with clinical, laboratory, and disease-specific parameters.

Keywords: arterial stiffness; atherosclerosis; augmentation index; cardiovascular disease; psoriatic arthritis; pulse wave velocity; rheumatoid arthritis; systemic lupus erythematosus; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Cardiovascular interplay (adapted from [23]).
Figure 2
Figure 2
Measurement of aortic stiffness via the carotid–femoral pulse wave velocity (cfPWV). L: distance between the carotid and femoral arteries, Δt: time needed for the pulse wave to travel between the two measurement points.

Similar articles

Cited by

References

    1. Deane K.D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: Focus on preclinical RA and SLE. Nat. Rev. Rheumatol. 2014;10:212–228. doi: 10.1038/nrrheum.2014.6. - DOI - PMC - PubMed
    1. Restivo V., Candiloro S., Daidone M., Norrito R., Cataldi M., Minutolo G., Caracci F., Fasano S., Ciccia F., Casuccio A., et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun. Rev. 2022;21:102925. doi: 10.1016/j.autrev.2021.102925. - DOI - PubMed
    1. Lu X., Wang Y., Zhang J., Pu D., Hu N., Luo J., An Q., He L. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis. Int. Immunopharmacol. 2021;94:107466. doi: 10.1016/j.intimp.2021.107466. - DOI - PubMed
    1. Tektonidou M.G. Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. J. Autoimmun. 2022;128:102813. doi: 10.1016/j.jaut.2022.102813. - DOI - PubMed
    1. Cen X., Feng S., Wei S., Yan L., Sun L. Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies. Medicine. 2020;99:e23009. doi: 10.1097/MD.0000000000023009. - DOI - PMC - PubMed

LinkOut - more resources